Загрузка...
Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates
Patients treated with bioproducts (BPs) frequently develop anti-drug antibodies (ADAs) with potential neutralizing capacities leading to loss of clinical response or potential hypersensitivity reactions. Many factors can influence BP immunogenicity and could be related to the patient, the treatment,...
Сохранить в:
| Опубликовано в: : | Front Immunol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7214678/ https://ncbi.nlm.nih.gov/pubmed/32431697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00725 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|